Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Journal Articles

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

Isabella Iasenza, Meaghan Boileau, BSc, Andrea Neumann, BSc., Héloïse Frison, MSc., Mark D. Minden, MD PhD, Isabelle Laverdiere, BPharm, MSc, PhD, Kolja Eppert, MSc, PhD

Blood (2019) 134 (Supplement_1): 5052.

https://doi.org/10.1182/blood-2019-125338

Published: 2019

Journal Articles

The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Dennis Dong Hwan Kim, MD, Taehyung Kim, MSc, Tracy Murphy, MDFRCP,FRCPath, Steven M Chan, MD PhD, Mark D. Minden, MD PhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 3299.

https://doi.org/10.1182/blood-2019-128281

Published: 2019

Journal Articles

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Matthew Tcheng, BSc, Alessia Roma, BSc, Nawaz Ahmed, MSc, Richard Smith, PhD, Preethi Jayanth, PhD, Mark D. Minden, MD PhD, Rose Hurren, BSc, Aaron D Schimmer, MD PhD, Gale Bozzo, PhD, David Hess, PhD, Kristin Hope, PhD, Kevin Rea, MSc, Tariq A. Akhtar, PhD, Al-Walid Mohsen, PhD, Jerry Vockley, MD PhD, Paul A. Spagnuolo, PhD

Blood (2019) 134 (Supplement_1): 3922.

https://doi.org/10.1182/blood-2019-122262

Published: 2019

Journal Articles

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

Oleksandr Galkin, PhD, Jessica McLeod, BSc, James A Kennedy, MD PhD, Liqing Jin, MD, Nathan Mbong, Mark Wong, PhD, Bob Uger, PhD, Mark D. Minden, MD PhD, Jayne S Danska, PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 3906.

https://doi.org/10.1182/blood-2019-131018

Published: 2019

Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 3940.

https://doi.org/10.1182/blood-2019-128450

Published: 2019

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Geethu Emily Thomas, PhDMSc,BSc, Grace Egan, MD, Laura Garcia Prat, Boaz Nachmias, MD PhD, Jordan M Chin, Fieke W Hoff, BSc, Kerstin Kaufmann, PhD, Rose Hurren, BSc, Marcela Gronda, MSc, Neil MacLean, Xiaoming Wang, Veronique Voisin, PhD, Aaron Botham, Andrea Arruda, Mark D. Minden, MD PhD, Gary D Bader, Steven M. Kornblau, MD, John E. Dick, PhD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2532.

https://doi.org/10.1182/blood-2019-123121

Published: 2019

Journal Articles

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

Tracy Murphy, MDFRCP,FRCPath, Stanley W.K. Ng, PhD, Tong Zhang, Ian King, PhD, Andrea Arruda, Jaime O. Claudio, PhD, Narmin Ibrahimova, Fiona Ferrera, Chantal Rockwell, Zhibin Lu, Natalie Stickle, Carl Virtanen, MSc, Brian Leber, MD, Mitchell Sabloff, MD, Mark D. Minden, MD PhD, Tracy L. Stockley, PhD FCCMG, FACMG, Steven M Chan, MD PhD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 2682.

https://doi.org/10.1182/blood-2019-130532

Published: 2019

Journal Articles

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Justin M. Watts, MD, Terrence J Bradley, MD, Amber Thomassen, Andrew M. Brunner, MD, Mark D. Minden, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Sameem Abedin, MD, Amanda J Baines, Olena Barbash, PhD, Shelby Gorman, Brandon E Kremer, MD PhD, Gautam M. Borthakur, MD

Blood (2019) 134 (Supplement_1): 2656.

https://doi.org/10.1182/blood-2019-130337

Published: 2019

Journal Articles

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Ruiqi Chen, MSc, Xing Liu, PharmD, Solaf Kanfar, MD, Dawn Maze, MDFRCPC,MSc, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, Anna Xu, Umberto Falcone, MD, Jack Seki, PharmD, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 1303.

https://doi.org/10.1182/blood-2019-124117

Published: 2019

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Blood (2019) 134 (Supplement_1): 729.

https://doi.org/10.1182/blood-2019-122784

Published: 2019

Journal Articles

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1424.

https://doi.org/10.1182/blood-2019-122890

Published: 2019

Journal Articles

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

Jenny M. Ho, MD, Jessie J.F. Medeiros, BSc, Michelle Chan-Seng-Yue, Lauren Hummel, BSc, Andrea Arruda, Amanda Mitchell, PhD, Caroline J McNamara, MBBS, James A Kennedy, MD PhD, Anne Tierens, MD PhD, Dawn Maze, MDFRCPC,MSc, Hubert Tsui, MD PhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 1676.

https://doi.org/10.1182/blood-2019-130923

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Blood (2019) 134 (Supplement_1): 5725.

https://doi.org/10.1182/blood-2019-129078

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Robert Puckrin, MD, Eshetu G Atenafu, M.Sc., P.Stat, Jaime Claudio, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Andre Schuh, Tracy Murphy, MDFRCP,FRCPath, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 436.

https://doi.org/10.1182/blood-2018-99-113090

Published: 2018

Journal Articles

AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis

Jenny M. Ho, MD, Jessie James Franco Medeiros, BSc, Michelle Chan-Seng-Yue, Lauren Hummel, BSc, Andrea Arruda, Amanda Mitchell, PhD, Caroline J McNamara, MBBS, James Kennedy, MD PhD, Anne Tierens, MD PhD, Hubert Tsui, MD PhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, John E. Dick, PhD

Blood (2018) 132 (Supplement 1): 4321.

https://doi.org/10.1182/blood-2018-99-118889

Published: 2018

Journal Articles

Genetic Analysis of B-Cell Acute Lymphoblastic Leukemia Dissemination to the Central Nervous System Identifies Clonal Selection and Therapeutic Vulnerability

Robert Vanner, MD PhD, Stephanie M. Dobson, PhD, Ildiko Grandal, MSc, Olga I. Gan, PhD, Jessica McLeod, BSc, James Kennedy, MD PhD, Veronique Voisin, PhD, Cynthia Guidos, PhD, Jayne S. Danska, PhD, Esme Waanders, PhD, Mark D. Minden, MD PhD, Charles G. Mullighan, MBBS, MD, John E. Dick, PhD

Blood (2018) 132 (Supplement 1): 1542.

https://doi.org/10.1182/blood-2018-99-115191

Published: 2018

Journal Articles

Myelofibrosis Is Initiated and Sustained By Rare Multipotent Stem Cells

Jessie J.F. Medeiros, BSc, Amanda Mitchell, PhD, Aaron Trotman-Grant, Tristan Woo, Jenny M. Ho, MD, Andrea Arruda, Mark D. Minden, MD PhD, John E. Dick, PhD, Vikas Gupta, MD FRCP, FRCPath, Liran I. Shlush, MD PhD

Blood (2018) 132 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2018-99-119088

Published: 2018

NARROW

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Novel Therapeutics That Can Target and Eradicate Leukemic Stem Cells in Acute Myeloid Leukemia: Investigating FDA-Approved Anti-Inflammatory Compounds

The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Inhibiting Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Induces Selective Leukemia Cell Death

Sirpαfc Treatment Targets Human Acute Myeloid Leukemia Stem Cells

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis

Genetic Analysis of B-Cell Acute Lymphoblastic Leukemia Dissemination to the Central Nervous System Identifies Clonal Selection and Therapeutic Vulnerability

Myelofibrosis Is Initiated and Sustained By Rare Multipotent Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only